For the quarter ending 2026-03-31, COCP made $225K in revenue. -$2,299K in net income. Net profit margin of -1021.78%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Grant income | 225 | - | - | - |
| Research and development | 1,371 | 1,941* | 954 | 1,122 |
| General and administrative | 1,210 | 783* | 1,135 | 986 |
| Total operating expenses | 2,581 | 2,723 | 2,089 | 2,108 |
| Loss from operations | -2,356 | -2,723* | -2,089 | -2,108 |
| Interest income, net | -22 | -59* | -22 | -28 |
| Foreign exchange loss, net | 35 | -10* | 18 | 25 |
| Total other income, net | 57 | 49* | 40 | 53 |
| Net loss | -2,299 | -2,675 | -2,049 | -2,055 |
| Basic EPS | -0.17 | -0.211 | -0.19 | -0.2 |
| Diluted EPS | -0.17 | -0.211 | -0.19 | -0.2 |
| Basic Average Shares | 13,786,000 | 12,705,000 | 10,991,000 | 10,174,000 |
| Diluted Average Shares | 13,786,000 | 12,705,000 | 10,991,000 | 10,174,000 |
Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc. (COCP)